Invest3 publishers2 min readPublished Updated
Olympus Partners collects two-thirds of Accelevation's $540 million IPO
Accelevation's $540 million Nasdaq IPO sends $360 million to private equity backer Olympus Partners and $180 million to the company, before underwriting fees. The company's share is slated to repay debt and cover the costs of the listing, with general corporate purposes listed last.
The Investor · Invest desk
Drafted by a language model from the sources cited here and checked against its claim ledger before publication. How we use AISend a correction
What happened
- Olympus-affiliated holders also gave underwriters a 30-day option to buy up to 4.5 million more shares at $18, less underwriting discounts and commissions.
- ACCV shares are due to start trading on the Nasdaq Global Select Market on September 30, 2026, with the offering expected to close on October 1.
- Accelevation, based in Miamisburg, Ohio, designs, manufactures and installs custom structural, electrical and mechanical systems for mission-critical infrastructure.
- Olympus, founded in 1988, is a middle-market buyout firm managing more than $12 billion, mostly for pension funds, endowments and state-sponsored retirement programs.
Compiled by The InvestorSomething wrong?How this is made
Why it matters
- cost With the option fully exercised, public buyers would hand Olympus's affiliates about $2.45 for every $1 of gross proceeds that reaches Accelevation.
- exposure Price risk on the 20 million shares Olympus's affiliates sell passes from a fund run for pension funds and endowments to public buyers paying $18.
- constraint Growth spending at a manufacturer with nationwide field crews gets only what is left of $180 million after discounts, debt repayment and listing costs are paid.
At $18 a share, $12 of every share sold in the base deal goes to stockholders affiliated with Olympus Partners and $6 goes to Accelevation [1]. The split follows the share count: 20 million of the 30 million shares are Olympus's and 10 million are new [2], and the company gets nothing from the shares its backer sells [3]. Even the $6 is gross, struck before underwriting discounts, commissions and other expenses [1]. Ten banks hold bookrunner roles, led by Morgan Stanley and J.P. Morgan [11][4].
The overallotment option can move that split in only one direction. All 4.5 million extra shares would come from the selling stockholders [4], so full exercise adds $81 million [5] and lifts the Olympus side to $441 million of $621 million, about 71% [2]. Accelevation's $180 million stays fixed, and its share of the money raised slips from a third to about 29% [3].
The company's portion, or rather what survives the underwriting discount, takes a short route. Accelevation will buy newly issued units in Accelevation Holdings LLC with its net proceeds [7]. The LLC will spend the money repaying indebtedness, covering the costs of the IPO and related organizational transactions, and on general corporate purposes [8]. The pricing report does not give amounts for those uses or a post-offering share count [12].
This reading is too harsh if the debt being repaid is expensive. Retiring costly debt helps every holder, buyers at $18 included [1]. It is also too harsh if Olympus still owns a large stake after selling its 20 million shares [2]. In that case the $360 million is a first instalment, and the value of what Olympus keeps depends on the ACCV price as much as any new holder's stake does [2][6].
I think the base case is the plain one. The deal turns two-thirds of a $540 million offering into cash for a private equity backer [1] and hands the company a sum that goes first to its lenders and to the costs of listing [8]. A post-offering ownership table showing Olympus still in control would change that view. ACCV would then be a partial float with its controlling owner still inside, a different security to price at $18 [1].
What to watch
- Whether underwriters take up all 4.5 million option shares within 30 days of pricing, lifting Olympus's cut from two-thirds to about 71%.
- Final prospectus figures for how much debt Accelevation Holdings LLC repays and how much of the company Olympus owns after the October 1 closing.
- How ACCV trades against its $18 offer price after its September 30 Nasdaq debut.